Ambeed.cn

首页 / / / / Dasatinib monohydrate

达沙替尼(一水合物) /Dasatinib monohydrate {[allProObj[0].p_purity_real_show]}

货号:A210354 同义名: BMS-354825 monohydrate

Dasatinib monohydrate(BMS-354825)是一种高效的ATP竞争性口服活性双重Src/Bcr-Abl抑制剂,具有显著的抗肿瘤活性。其对SrcBcr-Abl的Ki值分别为16 pM和30 pM,对Bcr-AblSrcIC50值分别为<1.0 nM和0.5 nM。达沙替尼一水合物还诱导细胞凋亡自噬

Dasatinib monohydrate 化学结构 CAS号:863127-77-9
Dasatinib monohydrate 化学结构
CAS号:863127-77-9
Dasatinib monohydrate 3D分子结构
CAS号:863127-77-9
Dasatinib monohydrate 化学结构 CAS号:863127-77-9
Dasatinib monohydrate 3D分子结构 CAS号:863127-77-9
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Dasatinib monohydrate 纯度/质量文件 产品仅供科研

货号:A210354 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JMC, 2024. Ambeed. [ A919389 , A918471 , A995972 ]
Anal. Chem., 2024, 96(50): 19947-19954. Ambeed. [ A261947 , A1165388 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A220462 ]
ACS Biomater. Sci. Eng., 2024. Ambeed. [ A165235 , A110205 ]
Pharmaceutics, 2024, 16(12): 1546. Ambeed. [ A272538 , A187261 , A691302 , A506702 ]
更多 >
产品名称 c-Kit 其他靶点 纯度
Tyrphostin AG1296 +

c-Kit (Swiss 3T3), IC50: 1.8 μM

PDGFR 99%+
Masitinib +

Kit, IC50: 200 nM

99%+
Motesanib Diphosphate +++

Kit, IC50: 8 nM

99% (HPLC)
Ki8751 ++

c-Kit, IC50: 40 nM

99%
Tivozanib ++

c-Kit, IC50: 78 nM

99%+
Pazopanib +

c-Kit, IC50: 140 nM

99%
Sitravatinib +++

Kit, IC50: 6 nM

99%+
Pexidartinib +++

Kit, IC50: 10 nM

99%+
Lactate ++++

c-Kit, IC50: 2 nM

FLT3 85%
Amuvatinib +++

c-Kit (D816H), IC50: 10 nM

99%+
Imatinib Mesylate +

c-Kit, IC50: 100 nM

PDGFR 99%
AZD2932 +++

c-Kit, IC50: 9 nM

99%
Axitinib ++++

Kit, IC50: 1.7 nM

98%
Dovitinib ++++

c-Kit, IC50: 2 nM

FLT3 99%+
Sunitinib FLT3 98%
OSI-930 +

Kit, IC50: 80 nM

99%+
Telatinib ++++

c-Kit, IC50: 1 nM

99%+
Dasatinib monohydrate ++

c-Kit (wt), IC50: 79 nM

c-Kit (D816V), IC50: 37 nM

Src 98%
Dasatinib ++

c-Kit (wt), IC50: 79 nM

c-Kit (D816V), IC50: 37 nM

Src 98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 ALK1 ALK2 ALK3 ALK4 ALK6 Smad3 TGF-β TGFβRI/ALK5 TGFβRII 其他靶点 纯度
LDN193189 ++++

ALK1, IC50: 0.8 nM

++++

ALK2, IC50: 0.8 nM

+++

ALK3, IC50: 5.3 nM

+++

ALK6, IC50: 16.7 nM

99%+
LDN-212854 ++++

ALK1, IC50: 2.4 nM

++++

ALK2, IC50: 1.3 nM

+

ALK3, IC50: 85.8 nM

+

ALK4, IC50: 2133 nM

+

ALK5, IC50: 9276 nM

99%+
ML347 ++

ALK1, IC50: 46 nM

++

ALK2, IC50: 32 nM

98%
K02288 ++++

ALK1, IC50: 1.8 nM

++++

ALK2, IC50: 1.1 nM

++

ALK3, IC50: 34.4 nM

+++

ALK6, IC50: 6.4 nM

99%+
LDN-193189 dihydrochloride ++++

ALK1, IC50: 0.8 nM

++++

ALK2, IC50: 0.8 nM

+++

ALK3, IC50: 5.3 nM

+++

ALK6, IC50: 16.7 nM

99%
LDN-214117 ++

ALK2, IC50: 24 nM

98%
DMH-1 +

ALK2, IC50: 107.9 nM

99%+
SB-505124 +

ALK4, IC50: 129 nM

++

ALK5, IC50: 47 nM

99%+
Vactosertib +++

ALK4, IC50: 13 nM

+++

ALK5, IC50: 11 nM

99%+
Alantolactone 98%
SIS3 97%
Pirfenidone 98%
Hesperetin 97%
RepSox ++++

TGFβR1(ALK5), IC50: 4 nM

98%
GW788388 +++

ALK5, IC50: 18 nM

98%
LY364947 ++

TGFβRI, IC50: 59 nM

+

TGFβRII, IC50: 0.4 μM

98%
SD-208 ++

TGF-βRI (ALK5), IC50: 48 nM

99%
SB-525334 +++

TGFβR1(ALK5), IC50: 14.3 nM

99%+
LY2109761 ++

TβRI, Ki: 38 nM

+

TβRII, Ki: 300 nM

99%+
Galunisertib ++

TβRI, IC50: 56 nM

98%
SB 431542 +

ALK5, IC50: 94 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Abl Bcr-Abl 其他靶点 纯度
NVP-BHG 712 +

c-Abl, IC50: 1.667 μM

99%+
KW-2449 +++

Abl (T315I), IC50: 4 nM

Abl, IC50: 14 nM

FLT3 99%+
Ponatinib ++++

Abl, IC50: 0.37 nM

98%
AT9283 99%+
Imatinib Mesylate +

v-Abl, IC50: 600 nM

PDGFR,c-Kit 99%
Danusertib ++

Abl, IC50: 25 nM

RET 99%+
Rebastinib ++++

p-Abl1 (native), IC50: 0.75 nM

u-Abl1 (T315I), IC50: 5 nM

FLT3,Tie-2 99%+
PP121 ++

Abl, IC50: 18 nM

PDGFR,VEGFR 99%+
GNF-7 +++

M351T, IC50: 133 nM

E255V, IC50: 122 nM

99%+
Olverembatinib dimesylate ++++

Abl, IC50: 0.34 nM

Abl (G250E), IC50: 0.35 nM

99%
Dasatinib monohydrate ++++

Abl , IC50: 0.6 nM

Src 98%
Dasatinib ++++

Abl, IC50: 0.6 nM

Src 98%
Bafetinib +++

Abl, IC50: 5.8 nM

98+%
GNF-2 +

Bcr-Abl (K562 cell line), IC50: 273 nM

Bcr-Abl (SUP-B15 cell line), IC50: 268 nM

98%+
Degrasyn +

Bcr-Abl, IC50: 1.8 μM

DUB 98+%
GNF-5 ++

Bcr-Abl, IC50: 220 nM

99%
Radotinib ++

BCR-ABL1, IC50: 34 nM

98+%
PD173955 Src 99%+
Nilotinib ++

Bcr-Abl, IC50: <30 nM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Fyn Lck Lyn Src Yes 其他靶点 纯度
Saracatinib ++

Fyn, IC50: 10 nM

++++

LCK, IC50: <4 nM

+++

Lyn, IC50: 5 nM

++++

c-Src, IC50: 2.7 nM

99%+
SU6656 +

Fyn, IC50: 170 nM

+

Lyn, IC50: 130 nM

+

Src, IC50: 280 nM

++

YES, IC50: 20 nM

98%
PP1 +++

Fyn, IC50: 6 nM

+++

LCK, IC50: 5 nM

EGFR 99%+
PP2 +++

Fyn, IC50: 5 nM

++++

LCK, IC50: 4 nM

98%
WH-4-023 ++++

Lck, IC50: 2 nM

+++

Src, IC50: 6 nM

99%+
NVP-BHG 712 +

c-Src, IC50: 1.266 μM

99%+
CCT196969 ++

LCK, IC50: 0.02 μM

+

Src, IC50: 0.03 μM

98%
MNS +

Src, IC50: 29.3 μM

Syk,p97 98%
Tirbanibulin ++

Src (HuH7), GI50: 13 nM

Src (Hep 3B), GI50: 26 nM

99%+
PP121 ++

Src, IC50: 14 nM

PDGFR,VEGFR 99%+
Bosutinib ++++

Src, IC50: 1.2 nM

99%
Dasatinib monohydrate ++++

Src, IC50: 0.8 nM

98%
Quercetin Sirtuin,PKC 97%
Dasatinib ++++

Src, IC50: 0.8 nM

98%
Repotrectinib +++

Src, IC50: 5.3 nM

99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Dasatinib monohydrate 生物活性

靶点
  • c-Kit

    c-Kit (wt), IC50:79 nM

    c-Kit (D816V), IC50:37 nM

  • Src

    Src, IC50:0.8 nM

  • Abl

    Abl , IC50:0.6 nM

描述 Dasatinib monohydrate, also known as BMS-354825 monohydrate, is an orally active, ATP-competitive dual Src/Bcr-Abl inhibitor with potent antitumor properties. It has Ki values of 16 pM for Src and 30 pM for Bcr-Abl. The IC50 values for inhibiting Bcr-Abl and Src are less than 1.0 nM and 0.5 nM, respectively. Dasatinib monohydrate exhibits significant activity against a range of targets including Bcr-Abl, Src, Lck, Yes, c-Kit, PDGFRβ, p38, Her1, Her2, FGFR-1, and MEK, with IC50 values of less than 1.0, 0.50, 0.40, 0.50, 5.0, 28, 100, 180, 720, 880, and 1700 nM, respectively. It shows antiproliferative effects on K562 chronic myelogenous leukemia (CML), PC3 human prostate cancer, MDA-MB-231 human breast cancer, and WiDr human colon cancer cell lines, with IC50 values of less than 1.0 nM, 9.4 nM, 12 nM, and 52 nM, respectively. Dasatinib monohydrate also induces apoptosis and autophagy in cells[1].

Dasatinib monohydrate 动物研究

Animal study The pharmacokinetic profile of Dasatinib monohydrate at 10 mg/kg is suitable for further in vivo efficacy studies, displaying favorable half-lives for both intravenous and oral administration, at 3.3 and 3.1 hours, respectively. The oral bioavailability observed in this study is 27%. At doses of 5 mg/kg and 50 mg/kg, administered once daily for 10 days with a 5 days on and 2 days off schedule, Dasatinib monohydrate demonstrates effective antitumor activity and high safety in a K562 CML xenograft model, resulting in complete tumor regression and low toxicity at multiple dose levels[1].

Dasatinib monohydrate 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02883049 B Acute Lymphoblastic Leukemia... 展开 >> Central Nervous System Leukemia Ph-Like Acute Lymphoblastic Leukemia Testicular Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia 收起 << Phase 3 Recruiting - -
NCT00390793 Acute Lymphoblastic Leukemia ... 展开 >> BCR-ABL1 Fusion Protein Expression Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive Recurrent Acute Lymphoblastic Leukemia t(9;22) 收起 << Phase 2 Active, not recruiting August 31, 2020 United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02143414 Acute Lymphoblastic Leukemia ... 展开 >> B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Philadelphia Chromosome Positive Recurrent Adult Acute Lymphoblastic Leukemia Refractory Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia 收起 << Phase 2 Recruiting - -

Dasatinib monohydrate 参考文献

[1]Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 Dec 30;47(27):6658-61.

Dasatinib monohydrate 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.88mL

1.98mL

0.99mL

19.76mL

3.95mL

1.98mL

Dasatinib monohydrate 技术信息

CAS号863127-77-9
分子式C22H28ClN7O3S
分子量 506.021
别名 BMS-354825 monohydrate
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 105 mg/mL(207.5 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

2% DMSO+30% PEG 300+dd water 5 mg/mL

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。